PROCEPT BioRobotics Corp (PRCT): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRCT Stock Price Chart Interactive Chart >
PRCT Price/Volume Stats
|Current price||$33.88||52-week high||$47.73|
|Prev. close||$32.65||52-week low||$15.38|
|Day high||$34.54||Avg. volume||396,325|
|50-day MA||$36.24||Dividend yield||N/A|
|200-day MA||$32.75||Market Cap||1.50B|
PROCEPT BioRobotics Corp (PRCT) Company Bio
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is based in Redwood City, California.
Most Popular Stories View All
PRCT Latest News Stream
|Loading, please wait...|
PRCT Latest Social Stream
View Full PRCT Social Stream
Latest PRCT News From Around the Web
Below are the latest news stories about PROCEPT BioRobotics Corp that investors may wish to consider to help them evaluate PRCT as an investment opportunity.
PROCEPT BioRobotics Corp. to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PROCEPT ® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report finical results for the fourth quarter and full year 2021 before market open on Tuesday, March 8, 2022. The companys management will webcast a corresponding conference call beginning at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time.
Procept BioRobotics'' Aquablation Therapy Shows Encouraging Five-Year Data In Prostate Gland Enlargement
Procept BioRobotics Corp (NASDAQ: PRCT ) announced five-year results from the WATER study comparing Aquablation therapy to TURP, the historical standard of care for treating benign prostatic hyperplasia (BPH). Procept is a surgical robotics company that develops, manufactures, and sells the AquaBeam Robotic Surgical System for minimally-invasive urologic surgery with an initial … Full story available on Benzinga.com
– Symptom reduction and uroflow improvement proved durable and consistent compared to TURP – Larger prostates (≥50 ml) demonstrated a larger safety and efficacy benefit for Aquablation over TURP – 5-year Aquablation retreatment rate was 51% less compared to TURP REDWOOD CITY, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced posi
PROCEPT BioRobotics Corp. to Present at 11th Annual SVB Leerink Global Healthcare Conference and Cowen’s 42nd Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present virtually at the following two investor conferences: 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17th, 2022, at 2:00 pm Pacific Time / 5:00 pm Eastern Time42nd Annual Cowen Health Care Conference
Investment company Sturgeon Ventures LLP (Current Portfolio) buys SentinelOne Inc, SentinelOne Inc, Cognex Corp, Informatica Inc, Alphabet Inc, sells Amazon.com Inc, Aptiv PLC, PayPal Holdings Inc, Pegasystems Inc, Meta Platforms Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Sturgeon Ventures LLP.
PRCT Price Returns